Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series

The COVID‐19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT‐P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased convenience relative to intravenous treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Vijayan, Sooraj, Hwangbo, Kyungmin, Barkham, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757239/
https://www.ncbi.nlm.nih.gov/pubmed/35059197
http://dx.doi.org/10.1002/ccr3.5233
_version_ 1784632649919234048
author Vijayan, Sooraj
Hwangbo, Kyungmin
Barkham, Nick
author_facet Vijayan, Sooraj
Hwangbo, Kyungmin
Barkham, Nick
author_sort Vijayan, Sooraj
collection PubMed
description The COVID‐19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT‐P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased convenience relative to intravenous treatment benefitting patients both during the pandemic and beyond.
format Online
Article
Text
id pubmed-8757239
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-87572392022-01-19 Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series Vijayan, Sooraj Hwangbo, Kyungmin Barkham, Nick Clin Case Rep Case Report The COVID‐19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT‐P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased convenience relative to intravenous treatment benefitting patients both during the pandemic and beyond. John Wiley and Sons Inc. 2022-01-13 /pmc/articles/PMC8757239/ /pubmed/35059197 http://dx.doi.org/10.1002/ccr3.5233 Text en © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Report
Vijayan, Sooraj
Hwangbo, Kyungmin
Barkham, Nick
Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series
title Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series
title_full Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series
title_fullStr Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series
title_full_unstemmed Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series
title_short Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series
title_sort real‐world evidence for subcutaneous infliximab (ct‐p13 sc) treatment in patients with ankylosing spondylitis during the coronavirus disease (covid‐19) pandemic: a case series
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757239/
https://www.ncbi.nlm.nih.gov/pubmed/35059197
http://dx.doi.org/10.1002/ccr3.5233
work_keys_str_mv AT vijayansooraj realworldevidenceforsubcutaneousinfliximabctp13sctreatmentinpatientswithankylosingspondylitisduringthecoronavirusdiseasecovid19pandemicacaseseries
AT hwangbokyungmin realworldevidenceforsubcutaneousinfliximabctp13sctreatmentinpatientswithankylosingspondylitisduringthecoronavirusdiseasecovid19pandemicacaseseries
AT barkhamnick realworldevidenceforsubcutaneousinfliximabctp13sctreatmentinpatientswithankylosingspondylitisduringthecoronavirusdiseasecovid19pandemicacaseseries

Ejemplares similares